Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.
You may also be interested in...
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
NeuroTherapeutics Taps Corporate Investors in $43 Million Series B Financing
With backing from GSK and Pfizer as well as traditional venture firms, NeuroTherapeutics Pharma plans to move a preclinical CNS drug into multiple clinical trials.